New research from the University of Michigan Comprehensive Cancer Center and Georgia Regents University finds that a protein that fuels an inflammatory pathway does not turn off in breast cancer, resulting in an increase in cancer stem cells. This provides a potential target for treating triple negative breast cancer, the most aggressive form of the disease.
Breast cancer stem cells exist in two different states and each state plays a role in how cancer spreads, according to an international collaboration of researchers. Their finding sheds new light on the process that makes cancer a deadly disease.
The research and development spending in the United States dropped from $131 billion to $119 billion, when adjusted for inflation, from 2007-2012, while Japan increased spending by $9 billion and China increased by $6.4 billion. Overall, Asia's share of spending grew from 18 percent to 24 percent. Europe held steady at 29 percent.
Patients with tongue cancer who started their treatment with a course of chemotherapy fared significantly worse than patients who received surgery first, according to a new study from researchers at the U-M Cancer Center. This is contrary to protocols for larynx cancer, in which a single dose of chemotherapy helps determine which patients fare better with chemotherapy and radiation and which patients should elect for surgery. In larynx cancer, this approach, which was pioneered and extensively researched at U-M, has led to better patient survival and functional outcomes.
Researchers at the University of Michigan Comprehensive Cancer Center have discovered a new class of drugs which reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments.
Researchers unravel mystery of how leukemia-causing mutations enable pre-leukemic stem cells to outperform their healthy counterparts
Researchers at the Children's Medical Center Research Institute at UT Southwestern, the University of California at San Francisco and the University of Michigan Comprehensive Cancer Center have discovered how leukemia-causing mutations enable pre-leukemic stem cells to outperform their healthy counterparts.
After 27 years leading the University of Michigan Comprehensive Cancer Center, founding director Max S. Wicha, M.D., has announced that he will step down as director. While serving as director, Wicha has continued to maintain his laboratory research and clinical practice seeing patients with breast cancer. In 2003, he was part of the team that first identified breast cancer stem cells.
For low-risk women, the likelihood that they get tested for the infection that causes cervical cancer (human papillomavirus or HPV) may depend on what clinic they visit, their doctor's status and whether their provider is male or female, a University of Michigan Health System study shows.
Researchers from the University of Michigan Comprehensive Cancer Center have identified a type of mutation that develops after breast cancer patients take anti-estrogen therapies. The mutations explain why patients become resistant to this therapy.
Researchers from the University of Michigan Comprehensive Cancer Center have identified new proteins that control the function of critical immune cell subsets called T-cells, which are responsible for a serious and often deadly side effect of lifesaving bone marrow transplants.